Phoenix, AZ, April 23, 2013 –(PR.com)– BumpeFace Razor Bump Fighter is designed for men and women who encounter the problem commonly known as Pseudofolliculitis Barbae (PFB): Irritation of the skin caused by shaving that leads to ingrown hairs and razor bumps. The BumpeFace Bar is available for purchase for $9.99 via online (http://www.bumpeface.com) and selected…
Editor’s ChoiceAcademic JournalMain Category: HIV / AIDS Article Date: 05 Apr 2013 – 0:00 PDT email to a friend printer friendly opinions <!– rate article Ad For Health Professionals Patient / Public: 5 (1 votes) Healthcare Prof: Researchers have charted a new route that could help develop a vaccine to boost a…
Main Category: HIV / AIDS Also Included In: Immune System / Vaccines Article Date: 05 Apr 2013 – 0:00 PDT email to a friend printer friendly opinions <!– rate article Ad For Health Professionals Patient / Public: Healthcare Prof: By tracking the very earliest days of one person’s robust immune response to…
Impairment in neurocognitive(NC) function in HIV-infected subjects in the current anti-retroviraltreatment (cART) era has been associated with poor compliance with cART, reduced quality-of-life and increased mortality. Reported factors associated with the development of NC function impairment in HIV disease and risks associated with progression of such impairment include degree of immune suppression related to HIV…
Main Category: Sexual Health / STDs Also Included In: HIV / AIDS; Women’s Health / Gynecology Article Date: 04 Apr 2013 – 1:00 PDT email to a friend printer friendly opinions <!– rate article Patient / Public: Healthcare Prof: Research led by David H. Martin, MD, Professor and Chief of Infectious Diseases at…
To date, all work related to the study of HIV tropism, was performed on HIV B and C subtypes. In the studied samples, HIV variants of subtype A were virtually absent. However, the existence has been shown previously of some differences in the nucleotide sequences in the V3 loop of env region of subtype A…
PRIMARY OBJECTIVES: I. To determine the safety and tolerability of XL184 (cabozantinib-s-malate) as a single agent in solid tumor patients with human immunodeficiency virus (HIV) infection and to determine the maximal tolerated dose (MTD) in this patient population. SECONDARY OBJECTIVES: I. To investigate possible pharmacokinetic interactions between cabozantinib and antiretroviral therapy in persons with HIV…
